EBS: Emergent Biosolutions Inc. Stocks News on June 5, 2025

5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost

EBS

Zacks

7 days ago

5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost

EBS

Zacks

17 days ago

Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions

5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes

EBS

Zacks

20 days ago

5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes

EBS

Argus Research

20 days ago

Daily – Vickers Top Buyers & Sellers for 05/16/2025

EBS

MT Newswires

21 days ago

Emergent Biosolutions Insider Bought Shares Worth $349,800, According to a Recent SEC Filing

Emergent BioSolutions to Participate in Upcoming Investor Conferences

EBS

GlobeNewswire

22 days ago

Emergent BioSolutions to Participate in Upcoming Investor Conferences

EBS

Thomson Reuters StreetEvents

a month ago

Q1 2025 Emergent BioSolutions Inc Earnings Call

Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid ...

EBS

GuruFocus.com

a month ago

Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid ...

Emergent Biosolutions (EBS) Q1 Earnings Top Estimates

EBS

Zacks

a month ago

Emergent Biosolutions (EBS) Q1 Earnings Top Estimates

EBS

Associated Press Finance

a month ago

Emergent Biosolutions: Q1 Earnings Snapshot

Emergent BioSolutions Reports First Quarter 2025 Financial Results

EBS

GlobeNewswire

a month ago

Emergent BioSolutions Reports First Quarter 2025 Financial Results

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

EBS

GlobeNewswire

a month ago

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

EBS

GlobeNewswire

a month ago

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?

EBS

Zacks

2 months ago

Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?

EBS

MT Newswires

2 months ago

Emergent BioSolutions Authorizes $50 Million Stock Buyback Program

Emergent BioSolutions Announces Stock Repurchase Program

EBS

GlobeNewswire

2 months ago

Emergent BioSolutions Announces Stock Repurchase Program

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

EBS

GlobeNewswire

3 months ago

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

EBS

GlobeNewswire

3 months ago

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

EBS

MT Newswires

3 months ago

Emergent BioSolutions Completes Sale of Baltimore-Bayview Facility to Syngene International

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

EBS

GlobeNewswire

3 months ago

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

EBS

GlobeNewswire

3 months ago

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

High Growth Tech Stocks In The US Market March 2025

EBS

Simply Wall St.

3 months ago

High Growth Tech Stocks In The US Market March 2025

Emergent signs financial investment agreement with Swiss Rockets

EBS

Pharmaceutical Technology

3 months ago

Emergent signs financial investment agreement with Swiss Rockets

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

EBS

GlobeNewswire

3 months ago

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

EBS

MT Newswires

3 months ago

Emergent BioSolutions to Invest in Swiss Rockets, Rocketvax

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

EBS

GlobeNewswire

3 months ago

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

EBS

MT Newswires

3 months ago

Emergent to Sell Baltimore-Bayview Facility for $36.5 Million

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

EBS

GlobeNewswire

3 months ago

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Emergent BioSolutions Inc. (NYSE:EBS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

EBS

Simply Wall St.

3 months ago

Emergent BioSolutions Inc. (NYSE:EBS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

EBS

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Emergent BioSolutions Inc Earnings Call

Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript

EBS

Motley Fool

3 months ago

Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript

Emergent BioSolutions Inc (EBS) Q4 2024 Earnings Call Highlights: Strategic Advancements Amid ...

EBS

GuruFocus.com

3 months ago

Emergent BioSolutions Inc (EBS) Q4 2024 Earnings Call Highlights: Strategic Advancements Amid ...

Emergent Biosolutions (EBS) Q4 Earnings Top Estimates

EBS

Zacks

3 months ago

Emergent Biosolutions (EBS) Q4 Earnings Top Estimates

EBS

MT Newswires

3 months ago

Emergent BioSolutions Swings to Q4 Earnings, Revenue Declines -- Shares Fall After Hours

EBS

Associated Press Finance

3 months ago

Emergent Biosolutions: Q4 Earnings Snapshot

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

EBS

GlobeNewswire

3 months ago

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

Emergent BioSolutions Inc. (NYSE:EBS) is favoured by institutional owners who hold 64% of the company

EBS

Simply Wall St.

3 months ago

Emergent BioSolutions Inc. (NYSE:EBS) is favoured by institutional owners who hold 64% of the company

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

EBS

GlobeNewswire

4 months ago

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

EBS

GlobeNewswire

4 months ago

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

Emergent seeking to reverse fortunes and become a major overdose treatment player

EBS

Pharmaceutical Technology

4 months ago

Emergent seeking to reverse fortunes and become a major overdose treatment player

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

EBS

GlobeNewswire

5 months ago

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

EBS

MT Newswires

5 months ago

Emergent BioSolutions Obtains Commercial Rights to Kloxxado Nasal Spray

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

EBS

GlobeNewswire

5 months ago

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

EBS

MT Newswires

5 months ago

Emergent Gets Contract Option With BARDA for Ebola Treatment

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

EBS

GlobeNewswire

5 months ago

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

Those who invested in Emergent BioSolutions (NYSE:EBS) a year ago are up 365%

EBS

Simply Wall St.

5 months ago

Those who invested in Emergent BioSolutions (NYSE:EBS) a year ago are up 365%

EBS

MT Newswires

5 months ago

Emergent BioSolutions Receives $20 Million Contract to Supply Anthrax Vaccine to US Military

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

EBS

GlobeNewswire

5 months ago

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

EBS

GlobeNewswire

5 months ago

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

Why Emergent BioSolutions Stock Blasted Higher Today

EBS

Motley Fool

5 months ago

Why Emergent BioSolutions Stock Blasted Higher Today

EBS

MT Newswires

5 months ago

Sector Update: Health Care Stocks Lower Monday Afternoon

EBS

MT Newswires

5 months ago

Emergent BioSolutions Shares Rise After HC Wainwright Begins Coverage With Buy Rating

Emergent Stock Skyrockets 251% YTD: How to Play the Stock?

EBS

Zacks

5 months ago

Emergent Stock Skyrockets 251% YTD: How to Play the Stock?

EBS

MT Newswires

6 months ago

Emergent BioSolutions Wins $50 Million Contract Option for Cyfendus; Shares Rise

Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

EBS

GlobeNewswire

6 months ago

Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

Why Emergent BioSciences Stock Plummeted Today

EBS

Motley Fool

6 months ago

Why Emergent BioSciences Stock Plummeted Today

EBS

MT Newswires

7 months ago

Emergent Biosolutions Insider Sold Shares Worth $272,750, According to a Recent SEC Filing

Emergent BioSolutions Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

EBS

Simply Wall St.

7 months ago

Emergent BioSolutions Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

EBS

GuruFocus.com

7 months ago

Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

EBS

Benzinga

7 months ago

Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

EBS

MT Newswires

7 months ago

Top Premarket Gainers

EBS

Zacks

7 months ago

New Strong Buy Stocks for November 7th

Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript

EBS

Motley Fool

7 months ago

Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript

Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates

EBS

Zacks

7 months ago

Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates

EBS

Associated Press Finance

7 months ago

Emergent Biosolutions: Q3 Earnings Snapshot

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

EBS

GlobeNewswire

7 months ago

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

Emergent BioSolutions Reports Third Quarter 2024 Financial Results

EBS

GlobeNewswire

7 months ago

Emergent BioSolutions Reports Third Quarter 2024 Financial Results

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

EBS

GlobeNewswire

7 months ago

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

EBS

Zacks

7 months ago

Zacks.com featured highlights include American Airlines, Air Canada, EmergentBioSolutions, Berry and Cracker Barrel Old Country Store

5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades

EBS

Zacks

7 months ago

5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

EBS

GlobeNewswire

7 months ago

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

EBS

Zacks

8 months ago

Zacks.com featured highlights include Grupo Supervielle, Emergent BioSolutions and Innodata

3 Stocks Poised for Better Returns With New Analyst Coverage

EBS

Zacks

8 months ago

3 Stocks Poised for Better Returns With New Analyst Coverage

Emergent BioSolutions Inc. (EBS): A Standout Among Best Performing Cheap Stocks in 2024

EBS

Insider Monkey

8 months ago

Emergent BioSolutions Inc. (EBS): A Standout Among Best Performing Cheap Stocks in 2024

Emergent BioSolutions Inc (EBS) Q2 2024 Earnings Call Highlights: Navigating Challenges and ...

EBS

GuruFocus.com

8 months ago

Emergent BioSolutions Inc (EBS) Q2 2024 Earnings Call Highlights: Navigating Challenges and ...

Emergent to donate 20,000 Narcan doses to fight opioid overdoses, CEO says

EBS

Pharmaceutical Technology

8 months ago

Emergent to donate 20,000 Narcan doses to fight opioid overdoses, CEO says

Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

EBS

GlobeNewswire

8 months ago

Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

EBS

MT Newswires

8 months ago

Emergent Enters New $100 Million Revolving Credit Agreement

Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility

EBS

GlobeNewswire

8 months ago

Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility

High Growth Tech Stocks To Watch This October 2024

EBS

Simply Wall St.

8 months ago

High Growth Tech Stocks To Watch This October 2024

EBS

MT Newswires

8 months ago

Emergent Biosolutions Awarded Contract Options Worth $67.4 Million

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

EBS

GlobeNewswire

8 months ago

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

EBS

MT Newswires

8 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday

EBS

MT Newswires

8 months ago

Sector Update: Health Care

EBS

MT Newswires

8 months ago

Emergent Biosolutions Receives $400 Million in Orders for Smallpox, Mpox Vaccines; Shares Rise 12% Pre-Bell

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

EBS

GlobeNewswire

8 months ago

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

Emergent BioSolutions Inc.'s (NYSE:EBS) institutional investors lost 16% last week but have benefitted from longer-term gains

EBS

Simply Wall St.

8 months ago

Emergent BioSolutions Inc.'s (NYSE:EBS) institutional investors lost 16% last week but have benefitted from longer-term gains

EBS

MT Newswires

9 months ago

Emergent Biosolutions Signs $40 Million Settlement Deal to Resolve 2021 Class Action

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

EBS

GlobeNewswire

9 months ago

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

EBS

MT Newswires

9 months ago

Emergent Biosolutions Awarded $41.9 Million Research, Development Option for Ebola Treatment

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

EBS

GlobeNewswire

9 months ago

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

BlackRock Inc. Reduces Stake in Emergent BioSolutions Inc.

EBS

GuruFocus.com

9 months ago

BlackRock Inc. Reduces Stake in Emergent BioSolutions Inc.

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

EBS

GlobeNewswire

9 months ago

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

EBS

MT Newswires

9 months ago

Emergent Biosolutions Closes $250 Million Credit Facility With Oak Hill Advisors

EBS

GlobeNewswire

9 months ago

Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile

EBS Stock Rises on FDA Nod for ACAM2000 in Mpox Indication

EBS

Zacks

9 months ago

EBS Stock Rises on FDA Nod for ACAM2000 in Mpox Indication

EBS

MT Newswires

9 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Friday

EBS

MT Newswires

9 months ago

Sector Update: Health Care

This Biotech Stock Surges As WHO Health Emergency Stirs FDA Approval

EBS

Investor's Business Daily

9 months ago

This Biotech Stock Surges As WHO Health Emergency Stirs FDA Approval

Emergent BioSolutions Stock Storms Higher After The FDA Signs Off On Mpox Vaccine

EBS

Investor's Business Daily

9 months ago

Latest Emergent Biosolutions Inc. (EBS) News on June 5, 2025

Share on Social Networks: